Abbott raises 2026 EPS guidance, reports pipeline progress across device portfolio
Abbott lifted its full-year adjusted EPS range to $5.45-$5.60 as it advanced trials in coronary lithotripsy, cardiac ablation, and left atrial appendage closure.
SEC filing